India consults on data requirements for drug trials, BA/BE studies
This article was originally published in SRA
India's Central Drugs Standard Control Organization has issued a draft guideline explaining proposed requirements for submission of chemical and pharmaceutical information, including stability study data, for the approval of clinical trial and bio-availability/bio-equivalence studies1.
You may also be interested in...
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-eight guidance documents have been posted on the tracker since its last update.
An international guideline on managing post approval changes to drugs, which was initially criticized because of its incompatibility with legal frameworks in certain ICH regions such as the EU, has been finalized.